AN2 Therapeutics, Inc. SEC Filings

AN2 Therapeutics (ANTX) filed an 8-K to announce it furnished a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information under Item 2.02 is being furnished, not filed.

The company lists its principal executive offices at 1300 El Camino Real, Suite 100, Menlo Park, CA 94025, and provides a former address at 1800 El Camino Real, Suite D, Menlo Park, CA 94027.

AN2 Therapeutics (ANTX) insider activity: Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 2,819 shares of common stock at $1.14 on November 4, 2025, to satisfy tax withholding from RSU vesting. Following the transaction, he beneficially owns 177,353 shares.

The holdings figure includes RSU grants: 31,500 RSUs vesting annually in quarters from November 4, 2024; 22,500 RSUs vesting annually in thirds from January 1, 2025; and 45,000 RSUs with two-thirds vesting on January 1, 2026 and one-third on July 1, 2026, subject to continuous service. The total also reflects the purchase of 5,000 shares under the 2022 ESPP on September 30, 2025.

AN2 Therapeutics (ANTX) reported an insider transaction by Chief Strategy Officer Stephen David Prior. On 11/04/2025, he sold 765 shares of common stock at $1.14 per share, a sale made to satisfy tax withholding from the vesting of RSUs. Following this transaction, he beneficially owned 65,548 shares.

His equity includes 10,125 RSUs that vest 1/4 annually over four years from November 4, 2024, and 12,031 RSUs that vest on January 1, 2026, each contingent on continued service. The holdings also reflect the purchase of 5,000 shares under the 2022 Employee Stock Purchase Plan on September 30, 2025.

AN2 Therapeutics (ANTX) reported a director’s acquisition of 10,367 shares of common stock on 10/10/2025 via Form 4. The shares were issued in lieu of cash compensation under the company’s non‑employee director policy, and all shares vest immediately. The transaction was coded A and reported at a price of $0. Following this transaction, the director beneficially owned 63,749 shares, held directly.

AN2 Therapeutics (ANTX) reported an insider transaction on a Form 4. Director Kabeer Aziz received 10,367 shares of common stock on 10/10/2025 as equity in lieu of cash under the non‑employee director compensation policy; all shares vest immediately at a reported price of $0.

Following the transaction, Aziz directly holds 40,919 shares. The filing also lists indirect holdings of 1,995,958 shares through Adjuvant Global Health Technology Fund, L.P. and 377,542 shares through Adjuvant Global Health Technology Fund DE, L.P., with standard disclaimers that beneficial ownership is disclaimed except to the extent of pecuniary interest.

AN2 Therapeutics (ANTX) reported an insider equity grant. Director Patricia A. Martin acquired 3,274 shares of common stock on 10/10/2025, issued in lieu of cash compensation under the company’s non-employee director compensation policy. The filing states these shares vest immediately. After this transaction, Martin beneficially owns 13,255 shares, held directly. The transaction price is shown as $0, reflecting a stock award rather than an open-market purchase.

AN2 Therapeutics (ANTX) reported interim results showing continued clinical progress and a tighter cash position. Total cash, cash equivalents and investments were $71.2 million as of June 30, 2025, with cash and cash equivalents of $18.22 million and short- and long-term investments of $44.70 million and $8.30 million, respectively. Management believes these resources are sufficient to fund the company’s current operating plan for at least 12 months.

The company recorded a $17.1 million net loss for the six months ended June 30, 2025 (versus $31.1 million in the comparable 2024 period), driven by research and development and general and administrative expenses. AN2 advanced AN2-502998 into Phase 1 start-up activities and completed dosing of the first single ascending dose cohort (reported events in May and August 2025). Funding arrangements include government and foundation awards, but a NIAID contract was reduced by $9.0 million to a cumulative $9.3 million commitment. The company continues to rely on external financing and grants while it advances multiple boron-chemistry programs.

AN2 Therapeutics reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The filing states that the information in Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and shall not be deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference in other filings except by specific reference. The report is dated August 12, 2025 and is signed by Chief Executive Officer Eric Easom.

AN2 Therapeutics, Inc. (ANTX) filed a Form 4 reporting a routine equity grant to director Kabeer Aziz. On 07/10/2025 Mr. Aziz received 11,875 shares of common stock issued in lieu of cash compensation under the company’s non-employee director compensation policy. Because the award was compensation, the shares were priced at $0.00 and vested immediately.

Following the grant, Mr. Aziz now directly holds 30,552 shares. He also has indirect beneficial ownership—through Adjuvant Global Health Technology Fund, L.P. (1,995,958 shares) and Adjuvant Global Health Technology Fund DE, L.P. (377,542 shares)—bringing total reported influence to roughly 2.404 million shares. However, the filing notes that voting and dispositive power is shared with the funds’ general partners and that beneficial ownership is disclaimed except for pecuniary interest.

No derivative securities, options, sales, or open-market purchases were reported, and no cash was exchanged. The transaction appears purely compensatory and does not signal a deliberate insider buy or sell decision. Investors typically view such awards as neutral unless the size represents a material percentage of total shares outstanding, which the filing does not disclose.